Transaction details
Beam Therapeutics Inc. (NASDAQ:BEAM) reported that Bethany Cavanagh, the company’s Senior Vice President, Finance and Treasurer, sold 3,242 shares of common stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were disposed of at $24.58 per share, producing a total transaction value of $79,688.
Following the sale, Cavanagh directly holds 51,171 shares of Beam Therapeutics. The filing indicates the disposition was executed to satisfy tax withholding obligations arising from the vesting of restricted stock units. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that the insider adopted on August 9, 2024.
Market context and valuation note
At the time of the filing, Beam’s stock was trading at $24.23 and had appreciated by more than 10% over the prior week. InvestingPro analysis referenced in the filing characterizes the shares as undervalued relative to their Fair Value. The filing also notes that InvestingPro subscribers can access 12 additional exclusive tips about BEAM, including commentary on the company’s strong balance sheet position.
Clinical updates
Separately, Beam published results from its Phase 1/2 BEACON clinical trial in The New England Journal of Medicine, centered on its therapeutic approach for sickle cell disease. The BEACON trial included 31 patients, with individual follow-up times ranging from 0.3 to 20.4 months.
The company also released clinical findings for BEAM-302 in alpha-1 antitrypsin deficiency, identifying a 60 mg dose as the pivotal dose for further development.
Analyst reactions
Following the clinical announcements, several brokerages and research firms adjusted or reiterated their coverage. Bernstein SocGen Group maintained an Outperform rating and a $40.00 price target. Leerink Partners raised its price target from $42 to $47 while keeping an Outperform stance. William Blair reiterated an Outperform rating, citing the high mean serum AAT levels observed in the BEAM-302 trial. Clear Street held a Buy rating with a $37.00 price target, highlighting that the identified dose confirms the optimal level for pivotal development.
Bottom line
The insider sale was executed under an established trading plan and was disclosed as tax-driven. At the same time, recent clinical publications and dose identification for BEAM-302 have drawn positive analyst attention and several Outperform or Buy ratings, indicating momentum around Beam’s clinical programs.
Summary
An insider sale by Beam’s treasurer covered tax obligations tied to vested RSUs and was conducted under a Rule 10b5-1 plan. Beam’s clinical disclosures for sickle cell disease and alpha-1 antitrypsin deficiency, including dose identification for BEAM-302 and BEACON trial data, have elicited positive analyst responses and updated price targets.